# US 6,730,296 B1 · Chimeric polypeptides containing chemokine domains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,296 B1
- Document ID: US6730296B1
- Status: Granted
- Kind: B1
- Application number: 09/467,638
- Filed: 1999-12-20
- Granted: 2004-05-04
- Earliest claimed: 1997-02-28
- Assignees: Wyeth
- Inventors: Stephen H. Herrmann; Stephen L. Swanberg
- Web page: https://patentgrep.com/patent/US6730296B1

## CPC

- C07K 14/523: {Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 47/6835: {the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/18: for HIV
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/522: {Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof.

## Claims

### Claim 1

A polypeptide produced according to a process comprising:
(a) growing a culture of a host cell in a suitable culture medium, wherein the host cell has been transformed with a polynucleotide comprising at least one expression control sequence, wherein the polynucleotide encodes a chimeric polypeptide, the chimeric polypeptide comprising at least one chemokine polypeptide covalently attached to at least one heterologous polypeptide, wherein the chemokine polypeptide comprises an amino acid sequence selected from the group consisting of:
(aa) SEQ ID NO:1;
(ab) SEQ ID NO:1 from amino acid 20 to amino acid 328;
(ac) SEQ ID NO:1 from amino acid 21 to amino acid 328;
(ad) SEQ ID NO:1 from amino acid 22 to amino acid 328;
(ae) SEQ ID NO:3; and
(af) SEQ ID NO:3 from amino acid 20 to amino acid 326, and
(b) purifying said polypeptide from the culture.

### Claim 2

A composition comprising a chimeric polypeptide, the chimeric polypeptide comprising at least one chemokine polypeptide covalently attached to at least one heterologous polypeptide, wherein the chemokine polypeptide comprises an amino acid sequence selected from the group consisting of:
(a) SEQ ID NO:1;
(b) SEQ ID NO:1 from amino acid 20 to amino acid 328;
(c) SEQ ID NO:1 from amino acid 21 to amino acid 328;
(d) SEQ ID NO:1 from amino acid 22 to amino acid 328;
(e) SEQ ID NO:3; and
(f) SEQ ID NO:3 from amino acid 20 to amino acid 326.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the chemokine polypeptide comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:1;
(b) the amino acid sequence of SEQ ID NO:1 from amino acid 20 to amino acid 328;
(b) the amino acid sequence of SEQ ID NO:1 from amino acid 21 to amino acid 328;
(c) the amino acid sequence of SEQ ID NO:1 from amino acid 22 to amino acid 328.

### Claim 4 (depends on 1)

The composition of claim 1 wherein the chemokine polypeptide comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:3;
(b) the amino acid sequence of SEQ ID NO:3 from amino acid 20 to amino acid 326.

### Claim 5 (depends on 1)

The composition of claim 1 wherein the chimeric polypeptide comprises the amino acid sequence of SEQ ID NO:1.

### Claim 6 (depends on 1)

The composition of claim 1 wherein the chimeric polypeptide comprises the amino acid sequence of SEQ ID NO:3.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

The polypeptide of claim 1 wherein the chemokine polypeptide comprises SEQ ID NO:1.

### Claim 9 (depends on 1)

The polypeptide of claim 1 wherein the chemokine polypeptide comprises SEQ ID NO:1 from amino acid 20 to amino acid 328.

### Claim 10 (depends on 1)

The polypeptide of claim 1 wherein the chemokine polypeptide comprises SEQ ID NO:1 from amino acid 21 to anino acid 328.

### Claim 11 (depends on 1)

The polypeptide of claim 1 wherein the chemokine polypeptide comprises SEQ ID NO:1 from amino acid 22 to amino acid 328.

### Claim 12 (depends on 1)

The polypeptide of claim 1 wherein the chemokine polypeptide comprises SEQ ID NO:3.

### Claim 13 (depends on 1)

The polypeptide to claim 1 wherein the chemokine polypeptide comprises SEQ ID NO:3 from amino acid 20 to amino acid 326.

### Claim 14 (depends on 2)

The composition of claim 2 wherein the chemokine polypeptide comprises SEQ ID NO:1 from amino acid 20 to amino acid 328.

### Claim 15 (depends on 2)

The composition of claim 2 wherein the chemokine polypeptide comprises SEQ ID NO:1 from amino acid 21 to amino acid 328.

### Claim 16 (depends on 2)

The composition of claim 2 wherein the chemokine polypeptide comprises SEQ ID NO:1 from amino acid 22 to amino acid 328.

### Claim 17 (depends on 2)

The composition of claim 2 wherein the chemokine polypeptide comprises SEQ ID NO:3 from amino acid 20 to amino acid 326.
